菜单
JP Medical Consulting Pty Ltd (ACN 673 260 056, JP Medical) is pleased to announce the appointment of Mr. Andrew Jaworski as Senior Vice President, Legal and Business Affairs Andrew Jaworski is a dual-qualified lawyer admitted in Australia, England, and Wales, with more than 20 years’ experience in corporate and commercial law across the pharma,…
阅读文章
JP Medical Consulting Pty Ltd (ACN 673 260 056, JP Medical) is pleased to announce the appointment of Mr. Neil Finlayson as Chief Operating Officer (COO). Mr. Neil Finlayson brings with him over 30 years of extensive experience in drug development, clinical development, project management, and commercialization. He has served as CEO of several vaccine…
阅读文章
JP Medical Consulting Pty Ltd (ACN 673 260 056, JP Medical) is pleased to announce the appointment of Ms. Nicoletta Muner as Senior Vice President, Global Regulatory Affairs. Ms. Nicoletta Muner brings over 25 years of experience in the pharmaceutical industry, covering product development, preclinical and clinical development, and international regulatory affairs. She is the…
阅读文章
Recently, Boji Medical Technology Co., Ltd. (hereinafter referred to as “Boji Medical”) and JP Medical Consulting Pty Ltd of Australia (hereinafter referred to as “JP Medical Consulting”) officially announced the establishment of a strategic partnership. This collaboration will integrate the clinical resources and professional strengths of both parties in the China–Australia pharmaceutical field, provide Chinese…
阅读文章
Queensland has long been an ideal destination for early-phase clinical trials. On May 20, the Shanghai–Queensland Biopharmaceutical Industry Development Seminar was successfully held at the Medical Device Innovation Center in the Lin-gang Special Area of Shanghai. The event brought together dozens of professionals from the biomedicine sector. Discussions focused on key topics such as Queensland’s…
阅读文章
On May 20, Xiying (Shanghai) Medical Technology Co., Ltd. (hereinafter referred to as “Xiying Medical”) and JP Medical Consulting Pty Ltd. of Australia (hereinafter referred to as “JP Medical Consulting”) officially signed a strategic cooperation agreement at the National Innovation Park of East China University of Science and Technology in Shanghai. The two parties will…
阅读文章
The Australia Pavilion at the 2025 DIA China Annual Meeting is hosted by the Commercial Section of the Australian Embassy and Consulates in China, together with the Australian Trade and Investment Commission (Austrade). It serves as a key platform to showcase Australia’s strengths in clinical trials and biotechnology. We invite you to visit Booth L16…
阅读文章
On August 20, following the strategic partnership between the two companies a few weeks ago, Ms. Helen Dai, Consul General of Australia in Chengdu and Head of Austrade, led a government team to visit Stam’s Shanghai office. Yu Wenhao, Senior Vice President and CBO of Stam Pharmaceutical, and Bao Yuanwu, General Manager of Shanghai and…
阅读文章
On July 24, Stam Pharmaceuticals (Beijing) Co., Ltd. (hereinafter referred to as “Stam Pharmaceuticals”) and JP Medical Consulting Pty Ltd (hereinafter referred to as “JP Medical Consulting”) of Australia announced a strategic cooperation. The cooperation aims to make full use of the clinical resources and professional advantages of both parties in the field of medicine…
阅读文章
In order to strengthen academic exchanges and cooperation with top international medical teams and promote high-quality development of disciplines, the Department of Obstetrics and Gynecology of the Second Affiliated Hospital of Chongqing Medical University invited Professor Mark von ltzstein, a fellow of the Royal Australian Institute of Chemistry, a fellow of the Australian Academy of…
阅读文章